Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
This study will explore whether a daily supplement of glycine, a substance that has antiinflammatory, cytoprotective, and endothelium-protecting effects, can improve mortality, as well as clinical and biochemical parameters, in patients with severe COVID-19 who initiate mechanical ventilatory support.
Description: Number of participants who die divided by number of subjects enrolled in the that study group.
Measure: Mortality Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Number of days spent under mechanical ventilation.
Measure: Days under mechanical ventilation Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Arterial pressure of oxygen divided by inspired fraction of oxygen.
Measure: PaO2/FiO2 ratio Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Plasma concentration of lactate in arterial blood.
Measure: Arterial plasma lactate Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of interleukin 1β.
Measure: Serum IL-1β Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of interleukin 2.
Measure: Serum IL-2 Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of interleukin 4.
Measure: Serum IL-4 Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of interleukin 5.
Measure: Serum IL-5 Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of interleukin 6.
Measure: Serum IL-6 Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of interleukin 7.
Measure: Serum IL-7 Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of interleukin 8.
Measure: Serum IL-8 Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of interleukin 10.
Measure: Serum IL-10 Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of interleukin 12 (p70).
Measure: Serum IL-12 Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of interleukin 13.
Measure: Serum IL-13 Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of interleukin 17A.
Measure: Serum IL-17 Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of granulocyte colony stimulating factor.
Measure: Serum G-CSF Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of granulocyte monocyte colony stimulating factor.
Measure: Serum GM-CSF Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of interferon gamma.
Measure: Serum IFN-γ Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of monocyte chemoattractant protein 1 (MCAF).
Measure: Serum MCP-1 Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of macrophage inflammatory protein 1β
Measure: Serum MIP-1β Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of tumor necrosis factor alpha.
Measure: Serum TNF-α Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of creatinine.
Measure: Serum creatinine Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of alanine aminotransferase. .
Measure: Serum alanine aminotransferase Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of aspartate aminotransferase. .
Measure: Serum aspartate aminotransferase Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of alkaline phosphatase.
Measure: Serum alkaline phosphatase Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of total bilirubin.
Measure: Serum total bilirubin Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of unconjugated bilirubin.
Measure: Serum unconjugated bilirubin Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of conjugated bilirubin
Measure: Serum conjugated bilirubin Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of C reactive protein.
Measure: Serum C reactive protein Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Blood concentration of hemoglobin.
Measure: Hemoglobin Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Number of white blood cells per µl blood.
Measure: Total leukocytes Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Number of neutrophils per µl blood.
Measure: Neutrophils Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Number of lymphocytes per µl blood.
Measure: Lymphocytes Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Number of monocytes per µl blood.
Measure: Monocytes Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Number of eosinophils per µl blood.
Measure: Eosinophils Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Number of basophils per µl blood.
Measure: Basophils Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Number of platelets per µl blood.
Measure: Platelets Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Time that blood takes to clot.
Measure: Prothrombin time Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Serum concentration of plasminogen activator inhibitor 1 (PAI-1).
Measure: Serum PAI-1 Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Sequence Organ Failure Assessment (SOFA) score, composed by assessment of PaO2/FiO2 ratio, Glasgow coma scale, mean arterial pressure, bilirubin, and platelets.
Measure: SOFA score Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Description: Acute Physiology And Chronic Health Evaluation II (APACHE II) score, composed by assessment of AaDO2 or PaO2, temperature, mean arterial pressure, pH arterial, heart rate, respiratory rate, sodium, potassium, creatinine, hematocrit, white blood cell count, Glasgow coma scale.
Measure: APACHE II score Time: From date of enrollment and until the date of weaning from ventilator or death, whichever came first, assessed up to 12 months.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports